← All trials
NCT07220902
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2026
- Primary completion
- Dec 31, 2033
- Completion date
- Jul 31, 2034
- First posted
- Oct 24, 2025
- Last posted
- Oct 24, 2025
- Enrollment
- 1240
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Nebraska Methodist Health SystemLead sponsor
- Nebraska Methodist Health SystemOfficial
- Nebraska Methodist Health SystemSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.